Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza

@inproceedings{Roberts2019RandomizedDP,
  title={Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Clinical Effect of Danirixin in Adults With Acute, Uncomplicated Influenza},
  author={Grace C Roberts and Shuguang Chen and Phillip J. Yates and Anuradha Madan and Jill Kerrick Walker and Michael L Washburn and Andrew J Peat and Gary Soucie and Edward M. Kerwin and Sumita Roy-Ghanta},
  booktitle={Open forum infectious diseases},
  year={2019}
}
Background Danirixin (DNX), a selective and reversible CXC chemokine receptor 2 antagonist, inhibits neutrophil transmigration and activation. This study assessed the safety, tolerability, and clinical effect of DNX with and without oseltamivir (OSV) in adults with acute, uncomplicated influenza. Methods This was a placebo-controlled, double-blind, Phase IIa study. Participants (18-64 years) with influenza-like symptoms (onset ≤48 hours) and positive influenza rapid antigen test were… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2.

VIEW 2 EXCERPTS

Research and developments of vaccines and drug treatments for influenza

  • K Lumbard, M. Ashton
  • Pharm J
  • 2017